Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Novel Rifaximin Formulations in Healthy Volunteers
NCT04529811Phase 1Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rifaximin in hepatic encephalopathy (HE), sickle cell anemia (SCA) and irritable bowel syndrome (IBS) (15 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Percentage of participants with adverse events up to 18 days. Started Sep 2020; status: completed.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)sickle cell anemia (SCA)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT04529811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04529811.